Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (41-50 of 162) with videos related to

Pageof 17
Sort By:
Lancet (London, England)|June 24, 2014
Adverse drug reaction: pomalidomide-induced liver injuryRajwanth R Veluswamy, Stephen C Ward, Kendra Yum, et al.
Frontiers in Immunology|December 1, 2018
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal AntibodiesGuido Lancman, Suzanne Arinsburg, Jeffrey Jhang, et al.
Cancers|October 2, 2019
A Network Analysis of Multiple Myeloma Related Gene SignaturesYu Liu, Haocheng Yu, Seungyeul Yoo, et al.
The American Journal of Gastroenterology|February 3, 2016
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice ExperienceAnjana A Pillai, Joel Wedd, J P Norvell, et al.
British Journal of Haematology|July 8, 2011
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemiaJohn Schindler, Srikanth Gajavelli, Farhad Ravandi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 19, 2017
RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMABGrenye O'Malley, Hanna J Lee, Samir Parekh, et al.
Therapeutic Advances in Hematology|February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myelomaLarysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
The effect of novel therapies in high-molecular-risk multiple myelomaGuido Lancman, Douglas Tremblay, Kevin Barley, et al.
Blood Advances|June 28, 2018
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modelingVernon Wu, Erin Moshier, Siyang Leng, et al.
The American Journal of Gastroenterology|November 12, 2009
Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosisRenumathy Dhanasekaran, Jonathan K West, Patrick C Gonzales, et al.
Pageof 17

Showing results (41-50 of 162) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|June 24, 2014
Adverse drug reaction: pomalidomide-induced liver injuryRajwanth R Veluswamy, Stephen C Ward, Kendra Yum, et al.
Frontiers in Immunology|December 1, 2018
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal AntibodiesGuido Lancman, Suzanne Arinsburg, Jeffrey Jhang, et al.
Cancers|October 2, 2019
A Network Analysis of Multiple Myeloma Related Gene SignaturesYu Liu, Haocheng Yu, Seungyeul Yoo, et al.
The American Journal of Gastroenterology|February 3, 2016
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice ExperienceAnjana A Pillai, Joel Wedd, J P Norvell, et al.
British Journal of Haematology|July 8, 2011
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemiaJohn Schindler, Srikanth Gajavelli, Farhad Ravandi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 19, 2017
RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMABGrenye O'Malley, Hanna J Lee, Samir Parekh, et al.
Therapeutic Advances in Hematology|February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myelomaLarysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
The effect of novel therapies in high-molecular-risk multiple myelomaGuido Lancman, Douglas Tremblay, Kevin Barley, et al.
Blood Advances|June 28, 2018
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modelingVernon Wu, Erin Moshier, Siyang Leng, et al.
The American Journal of Gastroenterology|November 12, 2009
Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosisRenumathy Dhanasekaran, Jonathan K West, Patrick C Gonzales, et al.
Pageof 17